Pelago Bioscience and AstraZeneca team up for cellular thermal shift assay (CETSA)
Pelago Bioscience and AstraZeneca have entered into a 2-year strategic research collaboration and license agreement.
The companies will collaborate on specified joint projects and AstraZeneca will also be granted a license to use and apply the CETSA for determination and quantification of drug–target interactions in other AstraZeneca discovery projects.
During the collaboration Pelago and AstraZeneca will together develop assay formats and applications of the CETSA method that are relevant to AstraZeneca’s range of therapeutic areas.
The companies will actively share information related to benchmarking and improvement in the use of the technology.
Michael Dabrowski, CEO of Pelago Bioscience, said: “We are very proud of this collaborative agreement with AstraZeneca. It will allow us to further improve the CETSA method using the knowledge and experience from one of the world’s largest drug discovery companies”
Mike Snowden, vice president discovery sciences AstraZeneca, said: “CETSA is an exciting technology that will allow us to examine the interaction between a drug candidate and its protein target within the cell.
“We are pleased to be exploring the potential of this platform in an open collaboration with the scientists at Pelago.”